PT-141
Bremelanotide
Regulatory Status
Bremelanotide has an FDA-approved branded form, while compounded sourcing remains a separate regulatory question.
FDA · Updated Apr 2026
Availability depends on local prescribing and import rules.
MHRA · Updated Apr 2026
Typically treated as prescription-only where available.
TGA · Updated Apr 2026
Not specifically listed in current WADA materials reviewed for this profile.
WADA · Updated Apr 2026
Overview
PT-141 is unusual in this group because bremelanotide has an FDA-approved drug form. That does not automatically resolve the broader questions around compounded peptide sourcing or off-label commercial positioning, which is why it still shows up in reclassification conversations.
State of Peptides 2026
Get the free report and peptide profile updates.
Evidence notes, regulatory changes, and practical research guides in your inbox. Education only - not medical advice.
Get the PeptideUnicorn update
New profiles, regulatory changes, practical guides, and vendor review notes delivered to your inbox.
Get our free State of Peptides 2026 report when you subscribe.